Cargando…

Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity

Several chemotherapeutics exert immunomodulatory effects. One of these is the nucleoside analogue gemcitabine, which is widely used in patients with lung cancer, ovarian cancer, breast cancer, mesothelioma and several other types of cancer, but with limited efficacy. We hypothesized that the immunop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lesterhuis, W. Joost, Salmons, Joanne, Nowak, Anna K., Rozali, Esdy N., Khong, Andrea, Dick, Ian M., Harken, Julie A., Robinson, Bruce W., Lake, Richard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633941/ https://www.ncbi.nlm.nih.gov/pubmed/23626745 http://dx.doi.org/10.1371/journal.pone.0061895

Ejemplares similares

Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations
por: Lesterhuis, W. Joost, et al.
Publicado: (2015)

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
por: Rozali, Esdy N., et al.
Publicado: (2012)

Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment
por: Aston, Wayne J., et al.
Publicado: (2019)

A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice
por: Aston, Wayne J., et al.
Publicado: (2017)

Restoration of defective cross-presentation in tumors by gemcitabine
por: McDonnell, Alison M, et al.
Publicado: (2015)

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations
por: Principe, Nicola, et al.
Publicado: (2022)

Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
por: Tilsed, Caitlin M., et al.
Publicado: (2022)

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
por: Hailemichael, Yared, et al.
Publicado: (2014)

Neoadjuvant anti-tumor vaccination prior to surgery enhances survival
por: Fisher, Scott A, et al.
Publicado: (2014)

Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen
por: Creaney, Jenette, et al.
Publicado: (2015)

MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
por: Miranda, Mariska, et al.
Publicado: (2015)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy
por: Tilsed, Caitlin M., et al.
Publicado: (2022)

Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade
por: Nakamoto, Nobuhiro, et al.
Publicado: (2009)

Transient Treg depletion enhances therapeutic anti‐cancer vaccination
por: Fisher, Scott A., et al.
Publicado: (2016)

Radiotherapy induces responses of lung cancer to CTLA-4 blockade
por: Formenti, Silvia C., et al.
Publicado: (2018)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Programmed Cell Death-Ligand 2: A Neglected But Important Target in the Immune Response to Cancer?
por: Solinas, Cinzia, et al.
Publicado: (2020)

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
por: Chen, Jiang, et al.
Publicado: (2023)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth
por: van der Most, Robbert G., et al.
Publicado: (2009)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
por: Zemek, Rachael M., et al.
Publicado: (2020)

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
por: Zhang, Jingyu, et al.
Publicado: (2017)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
por: Zhang, Shashuang, et al.
Publicado: (2020)

A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade
por: Philip, Hagit, et al.
Publicado: (2021)

CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade
por: Garcia-Perez, Josselyn E., et al.
Publicado: (2019)

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
por: Zhou, Yifan, et al.
Publicado: (2022)

Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
por: Marable, Jonathan, et al.
Publicado: (2021)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5l4kdla0cirbu1q2id6ljve7dk